UBS Group Lowers Evolent Health (NYSE:EVH) Price Target to $5.00

Evolent Health (NYSE:EVH) had its target price reduced by stock analysts at UBS Group from $10.00 to $5.00 in a research report issued on Thursday,Benzinga reports. The firm currently has a “buy” rating on the technology company’s stock. UBS Group’s price target would suggest a potential upside of 53.14% from the company’s current price.

EVH has been the topic of several other reports. Piper Sandler set a $6.00 price target on shares of Evolent Health in a research report on Tuesday, December 2nd. Citigroup dropped their target price on shares of Evolent Health from $9.50 to $6.00 and set a “buy” rating on the stock in a report on Friday, January 9th. Oppenheimer reduced their price target on Evolent Health from $18.00 to $12.00 and set an “outperform” rating for the company in a report on Wednesday, November 12th. Stephens raised Evolent Health from an “equal weight” rating to an “overweight” rating and set a $7.00 price target on the stock in a research report on Thursday, November 13th. Finally, Truist Financial cut their price objective on Evolent Health from $10.00 to $6.00 and set a “buy” rating for the company in a research report on Wednesday. Twelve analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $6.65.

Evolent Health Stock Up 4.0%

Shares of NYSE EVH traded up $0.13 during mid-day trading on Thursday, hitting $3.27. The company had a trading volume of 2,610,300 shares, compared to its average volume of 3,079,596. The company has a current ratio of 1.33, a quick ratio of 1.33 and a debt-to-equity ratio of 1.25. The firm has a 50-day simple moving average of $3.52 and a two-hundred day simple moving average of $5.85. The company has a market capitalization of $364.37 million, a PE ratio of -0.64 and a beta of 0.27. Evolent Health has a one year low of $2.50 and a one year high of $12.06.

Evolent Health (NYSE:EVH) last issued its quarterly earnings results on Tuesday, February 24th. The technology company reported $0.08 EPS for the quarter, beating the consensus estimate of $0.06 by $0.02. The firm had revenue of $468.72 million during the quarter, compared to analysts’ expectations of $468.48 million. Evolent Health had a positive return on equity of 1.30% and a negative net margin of 28.49%.The business’s quarterly revenue was down 27.5% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.02) earnings per share. On average, equities analysts expect that Evolent Health will post 0.08 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in EVH. Nisa Investment Advisors LLC grew its stake in shares of Evolent Health by 88.0% in the second quarter. Nisa Investment Advisors LLC now owns 2,551 shares of the technology company’s stock valued at $29,000 after acquiring an additional 1,194 shares in the last quarter. CIBC Private Wealth Group LLC boosted its holdings in Evolent Health by 4,000.0% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 4,100 shares of the technology company’s stock valued at $35,000 after purchasing an additional 4,000 shares during the period. Strs Ohio acquired a new position in shares of Evolent Health during the 1st quarter worth approximately $47,000. Vise Technologies Inc. acquired a new position in shares of Evolent Health during the 4th quarter worth approximately $50,000. Finally, Pilgrim Partners Asia Pte Ltd bought a new position in shares of Evolent Health during the third quarter worth approximately $51,000.

Evolent Health News Roundup

Here are the key news stories impacting Evolent Health this week:

• Positive Sentiment: Q4 results topped expectations — Evolent reported $0.08 EPS vs. $0.06 consensus and revenue of $468.7M (in line). The beat and the company’s commentary on execution are a near-term bullish trigger. Evolent Announces Fourth Quarter 2025 Results and Full Year 2025 Results (PR Newswire)
• Positive Sentiment: Earnings call highlighted strong oncology growth and strategic wins — management pointed to market-share gains, strong renewal rates and continued migration to enhanced Performance Suite contracts, supporting medium-term revenue opportunities. Q4 2025 Earnings Call Transcript (Seeking Alpha)
• Positive Sentiment: BTIG left a buy rating and set a new $8.00 target (down from $10) — still implies significant upside versus current levels and signals at least one institutional view that upside remains after the quarter. BTIG Research price target note
• Neutral Sentiment: FY2026 revenue guidance of $2.4B–$2.6B was provided and sits around consensus — the range keeps expectations steady but does not materially change the near-term story. FY2026 guidance in PR
• Neutral Sentiment: Headline coverage notes a sharp intraday move — media and retail attention (e.g., Yahoo Finance) likely amplified trading volume and the price bounce. That can produce short-term spikes without changing fundamentals. Evolent Health Shares Skyrocket (Yahoo Finance)
• Negative Sentiment: Royal Bank of Canada cut its target to $3.00 and moved to “sector perform” — this downgrade to a lower target adds selling pressure and signals more cautious institutional views. RBC price target note
• Negative Sentiment: Needham sharply cut its target from $15 to $4 while keeping a buy — the large reduction reduces the peg for upside and suggests lowered expectations for near-term recovery. Needham price target note
• Negative Sentiment: KeyCorp downgraded EVH from overweight to sector weight — another institutional shift toward caution that can weigh on sentiment and limit short-term rallies. Analyst downgrade coverage (TickerReport)

Evolent Health Company Profile

Evolent Health, Inc is a U.S.-based healthcare technology and services company that partners with health systems, physician organizations and health plans to design, build and operate value-based care programs. Headquartered in Arlington, Virginia, the company was founded in 2011 as a joint venture between TPG and the University of Pittsburgh Medical Center (UPMC). Evolent Health aims to help its clients transition from fee-for-service payment models to value-based care arrangements by leveraging its proprietary technology platforms and clinical expertise.

The company’s core offerings include care management solutions, population health analytics and clinical advisory services.